Development of an effective multiepitope vaccine against infectious laryngotracheitis virus based on envelope glycoproteins by immunoinformatics approaches

Document Type : Original Articles

Authors

1 Department of Hepatitis and HIV, Pasteur Institute of Iran, Tehran, Iran

2 Department of Hepatitis and HIV, Pasteur Institute of Iran, Tehran, Iran.

3 Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran

4 Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

5 Department of Pharmaceutical Biotechnology Faculty of Pharmacy Tabriz University of Medical Science, Tabriz, Iran

10.22092/ari.2025.367789.3431

Abstract

Infectious laryngotracheitis (ILT) is a significant respiratory disease that impacts poultry populations worldwide, known as infectious laryngotracheitis virus (ILTV). This viral disease presents considerable challenges not only to poultry health but also to the broader food industry, resulting in substantial economic losses and posing a risk to food security. The effective control and prevention of ILT are paramount, and vaccination strategies have emerged as critical measures in mitigating the impact of this disease. The envelope glycoproteins of ILTV are essential for the virus's ability to enter host cells, making them potential targets for vaccine development. However, until now, there has been a lack of comprehensive research focused on the evaluation of these glycoproteins for their immunogenic potential in the context of ILTV vaccination.
This study employs advanced bioinformatics tools to systematically analyze the antigenicity, sensitization, conservation, and intracellular localization of linear B-cell epitopes derived from the envelope glycoproteins of ILTV. Through this rigorous analysis, we identified four highly antigenic epitopes. To enhance their immunogenicity, we engineered multiple configurations of these linear B-cell epitopes using epitope folding techniques. Subsequently, we developed four multi-epitope vaccine candidates, each designed to incorporate two distinct adjuvants to bolster the immune response. Among these candidates, construct 1 exhibited optimal interactions with Toll-like receptors TLR2, TLR3, TLR4, and TLR5, resulting in significant levels of IFN-γ and IL-2 production. Following this, we performed codon optimization on this construct, which was then reverse transcribed and successfully cloned into the pET-28a vector. This critical step lays the groundwork for future in vitro and in vivo investigations aimed at evaluating the efficacy of the developed vaccine candidates in preventing ILT in poultry, ultimately contributing to enhanced biosecurity and economic stability in the poultry industry.

Keywords

Main Subjects